BIOMAT Database Logo BIOMAT Database Logo

A step forward for LRRK2 inhibitors in Parkinson's disease. 2022

Patrick A Lewis
Royal Veterinary College, London NW1 0TU, UK.

A phase 1 clinical trial for kinase inhibitors targeting LRRK2 provides the foundation for testing the efficacy of LRRK2 kinase inhibitors in Parkinson's disease.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071158 Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 A serine/threonine protein kinase with GTPase activity that contains 12 LEUCINE-rich repeats in its central region and 7 WD repeats C-terminal to its kinase and GTPase domains. It localizes to TRANSPORT VESICLES; the OUTER MITOCHONDRIAL MEMBRANE; and the GOLGI APPARATUS. It functions in PROTEIN TRANSPORT; regulates neuron morphology in the central nervous system, and also functions in the trafficking of SYNAPTIC VESICLES. Mutations in the LRRK2 gene have been identified in autosomal dominant cases of PARKINSON DISEASE (PARK8). Dardarin Protein,LRRK2 Protein,PARK8 Protein,Leucine Rich Repeat Serine Threonine Protein Kinase 2

Related Publications

Patrick A Lewis
Novel Macrocyclic LRRK2 Inhibitors for Treating Parkinson's Disease.
January 2022, ACS medicinal chemistry letters,
Patrick A Lewis
QSAR Modelling to Identify LRRK2 Inhibitors for Parkinson's Disease.
February 2019, Journal of integrative bioinformatics,
Patrick A Lewis
New Pyrrolopyrimidines as LRRK2 Inhibitors for Treating Parkinson's Disease.
August 2023, Current medicinal chemistry,
Patrick A Lewis
2-Aminoquinazolines as LRRK2 Inhibitors for Treating Parkinson's Disease.
May 2022, ACS medicinal chemistry letters,
Patrick A Lewis
Development of LRRK2 Inhibitors for the Treatment of Parkinson's Disease.
January 2017, Progress in medicinal chemistry,
Patrick A Lewis
Inhibitors of LRRK2 as Treatment for Parkinson's Disease: Patent Highlight.
September 2012, ACS medicinal chemistry letters,
Patrick A Lewis
Another Step Forward for Freezing of Gait in Parkinson's Disease.
January 2024, Journal of Parkinson's disease,
Patrick A Lewis
Pathophysiology of rigidity in Parkinson's disease: Another step forward.
August 2020, Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology,
Patrick A Lewis
Novel N-Heteroaryl Indazole Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.
April 2021, ACS medicinal chemistry letters,
Patrick A Lewis
Novel C-Linked Isoquinoline Amides as LRRK2 Inhibitors for Treating Parkinson's Disease.
June 2023, ACS medicinal chemistry letters,
Copied contents to your clipboard!